Pain at the vaccination site is a normal physiological reaction
Pain at the vaccination site is widely documented as a normal, self-limiting local physiological reaction reflecting standard innate immune activation and transient local inflammation.
The retrieved literature consistently confirms that local injection site pain and reactogenicity are standard, expected physiological responses following vaccination, driven by innate immune and inflammatory pathways. Numerous clinical studies and trials cite injection site pain as a very common and self-limiting side effect across various vaccine types. There is no evidence refuting this claim.
F. Briggs, F. Mateen, H. Schmidt, Keisha M. Currie, Heather Siefers, Slavka Crouthamel, B. Bebo, J. Fiol, M. Racke, K. O’Connor, Laura Kolaczkowski, Phyllis Klein, S. Loud, R. McBurney. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. 2021. https://doi.org/10.1212/NXI.0000000000001104
Paper 0 notes that pain at the injection site is among the most common self-limiting local reactions reported following vaccination.
See more details
K. Tomita, S. Okada, S. Sugihara, T. Ikeuchi, Hirokazu Touge, Junichi Hasegawa, A. Yamasaki. Physical Characteristics of Injection Site Pain After COVID-19 mRNA BNT162b2 Vaccination.. 2021. https://doi.org/10.33160/yam.2021.11.003
Paper 1 demonstrates that injection site pain is a prevalent side effect of mRNA vaccination associated with transient localized inflammation such as fasciitis.
C. Rostad, R. Atmar, E. Walter, S. Frey, J. Meier, Amy Sherman, Lilin Lai, Rachel Tsong, Carol M Kao, Vanessa Raabe, Hana M. El Sahly, W. Keitel, Jennifer A. Whitaker, Michael J. Smith, Kenneth E. Schmader, Geeta K. Swamy, G. Abate, P. Winokur, Wendy Buchanan, Kaitlyn A. Cross, A. Wegel, Yongxian Xu, Inci Yildirim, S. Kamidani, N. Rouphael, P. C. Roberts, Mark J. Mulligan, Evan J. Anderson. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.. 2024. https://doi.org/10.1093/cid/ciae173
Paper 4 indicates that injection site reactogenicity is a very common, expected, yet mostly mild to moderate occurrence following vaccination.
Yoon SK, Phillips AL, Calhoun S, Odom D, Ziemiecki R, Jackson L, McKell J, Griffin J, Choi JM, Prillaman BA, Campbell R, Hahn B, Warren B, Fix J, Rousculp MD, Ellsworth GL. mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and Their Relationship to Productivity for Healthcare Workers and First Responders.. 2026. https://doi.org/10.1093/ofid/ofag141
Paper 9 tracks solicited local reactogenicity symptoms including pain as standard real-world outcomes following COVID-19 vaccination.
Hollenbach J, Srivastava A, Chatzileontiadou D, Adhikari A, Suseno R, Lin S, Boquett J, Tuibeo J, Yusufali T, Peyser N, Farias T, Kichula K, Nguyen A, Jose I, Jayasinghe D, Leong S, Beatty A, Tarassi K, Kontou E, Maddumage J, Ampelakiotou K, Tsirogianni A, Dewar-Oldis M, Tu TM, Phan T, Barnard P, Sabatino J, Zoulas D, Ariens E, Mercer T, Grant E, D’Orsogna L, Smith C, Norman P, Marcus G, Olgin J, Pletcher MJ, Maiers M, Gras S. COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection. 2026. https://doi.org/10.21203/rs.3.rs-10085252/v1
Paper 10 establishes that localized transient vaccine side effects reflect normal innate inflammatory responses linked to protective immunity.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt